CNN reported on Wednesday that a study done in monkeys suggests Moderna's experimental COVID-19 vaccine might protect against severe disease and reduce the risk of passing the virus along to others.
US biotechnology company Moderna started advanced, Phase 3 testing of its experimental vaccine in humans in the US on 27 July 2020, the fastest advancement ever of a new vaccine in the US. However, the quick vaccine development process means the vaccine was not tested extensively in animals before moving on to people.
A team at the National Institute of Allergy and Infectious Diseases (NAID), which helped develop the vaccine, tested it in rhesus macaque monkeys. Then they infected the monkeys with the virus, an experiment that would be difficult, ethically, to do in human.
While the monkeys did become infected, the vaccine appeared to interfere with the spread of the virus in the animals, the NIAID team reported in The New England Journal of Medicine.
None of the monkeys that got the higher dose of vaccine had virus in their noses, either. That would suggest the vaccine might prevent the spread of the virus, even if people do get infected.
"This is the first time an experimental COVID-19 vaccine tested in nonhuman primates has been shown to produce such rapid viral control in the upper airway, the investigators note," the NAID researchers said.
"A COVID-19 vaccine that reduces viral replication in the lungs would limit disease in the individual, while reducing shedding in the upper airway would potentially lessen transmission of SARS-CoV-2 and consequently reduce the spread of disease," they added.
The researchers note that its not at all clear that monkeys respond to the virus in the same way that people do. But they noted that the virus appears to replicate in the noses of the monkeys in much the same way as it does in people.
Also, one worry was that the vaccine might make the body overreact to a true infection later on, a response known as vaccine-associated enhanced respiratory disease. This didn't happen in the monkeys, the researchers said.
CorMedix to acquire Melinta Therapeutics in USD300m deal to expand infectious disease portfolio
INOVIO to release Q2 2025 financial results on 12 August
Bavarian Nordic chikungunya vaccine enters Health Canada review process
Ondine Biomedical completes world-first ICU study with Steriwave nasal therapy
Centivax raises USD45m to commercialise universal flu vaccine
SCG Cell's SCG101V therapy Investigational New Drug Application receives Chinese regulatory approval
INOVIO prices USD25m public offering
Blacksmith Medicines granted US patent for antibacterial compounds targeting LpxC
Seegene launches STAgora infectious disease analytics platform
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results
Immuno Cure and PharmaJet collaborate for novel HIV therapeutic DNA vaccine advancement
Oxurion signs LOI to acquire majority stake in preclinical microbiology CRO
bioMérieux acquires Day Zero Diagnostics assets to expand rapid sequencing diagnostics
EDX Medical and Spire Healthcare sign strategic diagnostic partnership agreement